Introduction
============

Endotoxin plays a crucial role in the pathogenesis of severe sepsis and septic shock (SS&SSh) \[[@B1]\]. The aim of this study is to analyze the impact of extracorporeal endotoxin removal with polymyxin B hemoperfusion (PMX-DHP) (Toraymyxin^®^).

Methods
=======

All patients admitted to our ICU between 1 April 2011 and 30 June 2013 who developed SS&SSh and underwent endotoxin activity assay (EAA) measurement were retrospectively evaluated.

Results
=======

During the study period, EAA was dosed in 100 patients. Eighty- one patients were affected by septic shock. The source of infection was identified in 70.4% of cases (45% abdominal) and the percentage of microbiologically confirmed episodes was 77% (81% Gram-negatives). The mortality rate was 49%. The mean EAA level was 0.66 ± 0.2, and in 66% of patients the value was higher than 0.6. No significant differences were found in terms of SAPS II (*P*= 0.32) and SOFA score (*P*= 0.67), according to EAA level (\>/≤0.6). Patients with levels \>0.6 presented a higher percentage of microbiologically confirmed infections (84% vs. 66%; *P*= 0.09). Thirty-two of 66 patients with EAA \>0.6 were treated with Toraymyxin^®^. No complications leading to treatment interruption were recorded and a relevant decrease of cardiovascular SOFA score and lactate levels were observed 72 hours after treatment (*P*= 0.05 and *P*= 0.06, respectively). Source control and Toraymyxin^®^treatment resulted as the only modifiable factors improving the ICU survival rate (Table [1](#T1){ref-type="table"}).

###### 

Multivariate analysis for ICU mortality risk factors

                   *P*value   OR (95% CI)
  ---------------- ---------- -------------------
  SAPS II score    0.04       1.1 (1.01 to 1.1;
  Septic shock     0.02       10.4 (1.5 to 71)
  PMX-DHP          0.04       0.2 (0.1 to 0.9)
  Source control   0.01       0.1 (0.03 to 0.5)

Conclusion
==========

EAA is a rapid and reliable method to identify patients who may be treated with polymyxin B hemoperfusion. Source control and extracorporeal endotoxin removal have appeared as two effective interventions that should be implemented in the early management of patients with SS&SSh.
